

Disclaimer

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp017, Report 2 of 3

Request ID: cder_mpl1r_wp017_nsdv_v01

Request Description: The goal of this request was to identify medication errors due to look-a-like and sound-a-like name confusion of Brintellix and Brilinta. This report contains estimated numbers of Brintellix users and Brilinta users. Users with the appropriate on- or off-label indication were evaluated in addition to users without the appropriate indication and with an on- or off-label indication for the other drug of interest. This is report 2 of 3. Report 1 contains estimates of Brintellix and Brilinta users with only on-label indications for each drug. Report 3 contains estimates of Brilinta users that have a subsequent Brintellix dispensing and numbers of Brintellix users that have a subsequent Brilinta dispensing.

Sentinel Modular Program Tool Used: Cohort Identification and Descriptive Analysis (CIDA) tool, version 2.0

Data Source: Data from September 30, 2013 to September 30, 2015 from 16 Data Partners contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed to Data Partners on August 30, 2016.

Study Design: This request was designed to calculate background rates of users. The number of qualifying patients with the exposure of interest, number of eligible members, and member days were calculated overall and were stratified by age group, sex, and year.

Exposure of Interest: The exposures of interest were Brintellix and Brilinta, which were defined by National Drug Codes (NDCs). Please refer to Appendix A for generic and brand names used to define the drug exposures in this request.

Cohort Eligibility Criteria: Those included in the cohort were required to be continuously enrolled in plans with medical and drug coverage for at least 6 months (183 days) prior to their dispensing date, during which gaps in coverage of up to 45 days were allowed, and for at least 30 days after the dispensing date. Members were excluded if they had a prior history of the exposure of interest in the 6 months (183 days) prior to the index-defining dispensing. The following age groups were included in the cohort: 0-17, 18-44, 45-64, and 65+ years. All qualifying incident exposures that occurred between September 30, 2013 and September 30, 2015 were examined.

Inclusion/Exclusion Criteria: In addition to all users, users with and without an on- or off-label indication for each exposure were evaluated.

For Brilinta users, specific inclusion/exclusion groups included:

- 1) users with an indication for Brilinta
- 2) users with an indication for Brilinta and without an indication for Brintellix
- 3) users with an indication for Brintellix and without an indication for Brilinta

For Brintellix users, specific inclusion/exclusion groups included:

- 1) users with an indication for Brintellix
- 2) users with an indication for Brintellix and without an indication for Brilinta
- 3) users with an indication for Brilinta and without an indication for Brintellix

Inclusion and exclusion criteria were evaluated in the 183 days prior to the dispensing of interest. On-label indications for Brintellix are depression diagnoses, and on-label indications for Brilinta are acute coronary syndrome (ACS) or myocardial infarction (MI) diagnoses. Off-label indications for Brintellix include schizophrenia, episodic mood disorder, anxiety disorder, personality disorder, bipolar depression, chronic pain, or post-traumatic stress disorder diagnoses. Off-label indications for Brilinta include peripheral arterial disease, unstable angina, or stroke diagnoses, or stent procedures. Indications were defined by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes. Please refer to Appendix B for a list of specific ICD-9-CM codes used to define the indications for each cohort.

Overview for Request: cder_mpl1r_wp017, Report 2 of 3, continued

Sensitivity Analyses: A sensitivity analysis examined a longer inclusion/exclusion evaluation period, in which indications were evaluated in the 1 year (365 days) prior to the dispensing of interest. Users were also required to be continuously enrolled in plans with both medical and drug coverage for at least 1 year (365 days) prior to their dispensing date, during which gaps in coverage of up to 45 days were allowed.

Please see Appendix C for the specifications of parameters used in the analyses for this request.

Limitations: Algorithms to define exposures and indications are imperfect and may not have been validated; thus it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center Query Fulfillment Team (qf@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

Table of Contents

<u>Glossary</u>	List of Terms Found in this Report and their Definitions
<u>Table 1a</u>	Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication and Inclusion/Exclusion Period
<u>Table 1b</u>	Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication and Inclusion/Exclusion Period
<u>Table 2a</u>	Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015 by On- or Off-Label Indication, Inclusion/Exclusion Period, and Age Group
<u>Table 2b</u>	Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015 by On- or Off-Label Indication, Inclusion/Exclusion Period, and Age Group
<u>Table 3a</u>	Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Sex
<u>Table 3b</u>	Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Sex
<u>Table 4a</u>	Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Year
<u>Table 4b</u>	Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Year
<u>Appendix A</u>	List of Generic and Brand Drug Names Used to Define Exposures in this Request
<u>Appendix B</u>	List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request
<u>Appendix C</u>	Specifications for Parameters for this Request

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Tool*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt" value in the MSCDM.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). Along with the Principal Diagnosis Indicator, forms the Care Setting/PDX parameter.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 1: Cohort includes only the first valid incident treatment episode during the query period; 2: Cohort includes all valid incident treatment episodes during the query period; 3: Cohort includes all valid incident treatment episodes during the query period until an event occurs.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the MP algorithm: 0: Counts all occurrences of an HOI during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode.

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Lookback Period (pre-existing condition) - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Member-Years - sum of all days of enrollment with medical and drug coverage** in the query period preceded by an exposure washout period all divided by **365.25**.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Treatment Episode Truncation Indicator - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident query code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the incident query code.

Users - number of members with exposure during the query period. Member must have no evidence of exposure(s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.

Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event

Table 1a. Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication and Inclusion/Exclusion Period

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member-Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
All Brilinta Users													
183-Day Inclusion/Exclusion Period	23,102	23,261	92,602	3,151,739	6,271,359	9,253.8	59,037,824	68,628,708.6	0.39	136.43	4.01	34.04	100.0%
365-Day Inclusion/Exclusion Period	19,936	20,075	80,725	2,751,685	5,474,906	8,074.1	46,471,030	58,016,084.4	0.43	138.03	4.05	34.09	100.0%
Brilinta Users with an Indication for Brilinta													
183-Day Inclusion/Exclusion Period	22,436	22,546	90,446	3,077,679	6,125,679	9,030.4	2,784,546	1,940,823.3	8.06	137.18	4.03	34.03	97.1%
365-Day Inclusion/Exclusion Period	19,537	19,659	79,395	2,705,298	5,383,588	7,935.0	2,679,321	2,431,274.5	7.29	138.47	4.06	34.07	98.0%
Brilinta Users with an Indication for Brilinta and No Indication for Brintellix													
183-Day Inclusion/Exclusion Period	16,625	16,669	69,232	2,371,301	4,722,364	6,935.6	2,266,096	1,337,752.8	7.34	142.63	4.16	34.25	72.0%
365-Day Inclusion/Exclusion Period	13,654	13,699	57,885	1,986,035	3,956,772	5,801.7	2,011,492	1,556,031.1	6.79	145.45	4.24	34.31	68.5%
Brilinta Users with an Indication for Brintellix and No Indication for Brilinta													
183-Day Inclusion/Exclusion Period	132	132	348	11,300	22,028	34.8	9,710,585	6,710,376.2	0.01	85.61	2.64	32.47	0.6%
365-Day Inclusion/Exclusion Period	90	90	224	7,710	15,060	23.7	8,669,435	7,474,176.5	0.01	85.67	2.49	34.42	0.5%

Table 1b. Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication and Inclusion/Exclusion Period

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member-Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
All Brintellix Users													
183-Day Inclusion/Exclusion Period	22,019	22,161	66,539	2,117,909	2,174,719	6,415.6	59,042,169	68,639,184.6	0.37	96.19	3.02	31.83	100.0%
365-Day Inclusion/Exclusion Period	18,793	18,918	57,549	1,834,597	1,884,043	5,551.2	46,474,433	58,025,411.3	0.40	97.62	3.06	31.88	100.0%
Brintellix Users with an Indication for Brintellix													
183-Day Inclusion/Exclusion Period	18,753	18,855	57,023	1,814,225	1,866,084	5,490.9	10,210,440	7,564,591.3	1.84	96.74	3.04	31.82	85.2%
365-Day Inclusion/Exclusion Period	16,639	16,740	51,266	1,634,957	1,681,621	4,943.1	9,295,731	8,611,863.3	1.79	98.26	3.08	31.89	88.5%
Brintellix Users with an Indication for Brintellix and No Indication for Brilinta													
183-Day Inclusion/Exclusion Period	18,075	18,175	54,965	1,750,315	1,800,598	5,297.3	9,709,500	6,700,891.3	1.86	96.84	3.04	31.84	82.1%
365-Day Inclusion/Exclusion Period	15,766	15,864	48,654	1,552,288	1,596,976	4,692.6	8,668,254	7,464,935.2	1.82	98.46	3.09	31.90	83.9%
Brintellix Users with an Indication for Brilinta and No Indication for Brintellix													
183-Day Inclusion/Exclusion Period	73	73	260	9,087	9,237	26.8	2,273,533	1,349,656.3	0.03	124.48	3.56	34.95	0.3%
365-Day Inclusion/Exclusion Period	71	71	178	7,151	7,301	21.4	2,016,969	1,568,540.7	0.04	100.72	2.51	40.17	0.4%

Table 2a. Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015 by On- or Off-Label Indication, Inclusion/Exclusion Period, and Age Group

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
All Brilinta Users													
<i>183-Day Inclusion/Exclusion Period</i>													
0-17 Years	1	1	1	30	60	0.1	11,585,169	12,683,700.2	0.00	30.00	1.00	30.00	100.0%
18-44 Years	986	988	4,904	155,988	311,015	453.3	23,228,280	23,734,081.8	0.04	158.20	4.97	31.81	100.0%
45-64 Years	9,812	9,877	44,767	1,455,454	2,898,888	4,252.2	17,479,775	20,036,780.1	0.56	148.33	4.56	32.51	100.0%
65+ Years	12,307	12,395	42,930	1,540,267	3,061,396	4,548.2	9,152,828	12,174,146.5	1.34	125.15	3.49	35.88	100.0%
<i>365-Day Inclusion/Exclusion Period</i>													
0-17 Years	1	1	1	30	60	0.1	9,149,408	10,574,898.7	0.00	30.00	1.00	30.00	100.0%
18-44 Years	784	786	4,085	129,368	257,865	375.2	17,601,263	19,249,717.4	0.04	165.01	5.21	31.67	100.0%
45-64 Years	8,346	8,397	38,684	1,257,801	2,505,553	3,670.7	14,150,653	17,321,492.7	0.59	150.71	4.64	32.51	100.0%
65+ Years	10,809	10,891	37,955	1,364,486	2,711,428	4,028.1	7,630,385	10,869,975.6	1.42	126.24	3.51	35.95	100.0%
Brilinta Users with an Indication for Brilinta													
<i>183-Day Inclusion/Exclusion Period</i>													
0-17 Years	0	0	0	0	0	0.0	12,364	5,439.2	0.00	---	---	---	0.0%
18-44 Years	938	939	4,779	151,590	302,339	439.9	120,220	56,203.0	7.80	161.61	5.09	31.72	95.1%
45-64 Years	9,499	9,543	43,814	1,424,717	2,838,052	4,158.0	794,894	467,289.8	11.95	149.99	4.61	32.52	96.8%
65+ Years	12,003	12,064	41,853	1,501,372	2,985,288	4,432.4	1,902,401	1,411,891.4	6.31	125.08	3.49	35.87	97.5%
<i>365-Day Inclusion/Exclusion Period</i>													
0-17 Years	0	0	0	0	0	0.0	11,901	7,002.1	0.00	---	---	---	0.0%
18-44 Years	759	761	4,000	126,488	252,225	366.6	115,209	72,433.3	6.59	166.65	5.27	31.62	96.8%
45-64 Years	8,149	8,190	38,047	1,236,870	2,464,047	3,607.2	760,322	585,562.5	10.72	151.78	4.67	32.51	97.6%
65+ Years	10,633	10,708	37,348	1,341,940	2,667,316	3,961.2	1,844,890	1,766,276.5	5.76	126.21	3.51	35.93	98.4%
Brilinta Users with an Indication for Brilinta and No Indication for Brintellix													
<i>183-Day Inclusion/Exclusion Period</i>													
0-17 Years	0	0	0	0	0	0.0	11,396	4,659.8	0.00	---	---	---	0.0%
18-44 Years	687	688	3,696	117,364	233,887	339.8	89,635	35,268.9	7.66	170.84	5.38	31.75	69.7%
45-64 Years	7,033	7,046	33,776	1,097,698	2,188,420	3,193.4	608,115	295,139.0	11.57	156.08	4.80	32.50	71.7%
65+ Years	8,905	8,935	31,760	1,156,239	2,300,057	3,402.4	1,586,426	1,002,685.1	5.61	129.84	3.57	36.41	72.4%
<i>365-Day Inclusion/Exclusion Period</i>													
0-17 Years	0	0	0	0	0	0.0	10,736	5,845.4	0.00	---	---	---	0.0%
18-44 Years	541	542	3,036	95,681	190,611	276.6	79,280	42,711.3	6.82	176.86	5.61	31.52	69.0%
45-64 Years	5,757	5,767	28,094	913,265	1,821,458	2,654.0	532,469	343,498.6	10.81	158.64	4.88	32.51	69.0%
65+ Years	7,356	7,390	26,755	977,089	1,944,703	2,871.1	1,419,909	1,163,975.8	5.18	132.83	3.64	36.52	68.1%



Table 2a. Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015 by On- or Off-Label Indication, Inclusion/Exclusion Period, and Age Group

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
Brilinta Users with an Indication for Brintellix and No Indication for Brilinta													
<i>183-Day Inclusion/Exclusion Period</i>													
0-17 Years	0	0	0	0	0	0.0	675,093	426,533.1	0.00	---	---	---	0.0%
18-44 Years	22	22	49	1,930	3,740	5.8	3,525,549	2,195,604.6	0.01	87.73	2.23	39.39	2.2%
45-64 Years	58	58	124	3,964	7,808	12.6	3,540,281	2,457,517.6	0.02	68.34	2.14	31.97	0.6%
65+ Years	52	52	175	5,406	10,480	16.3	2,255,249	1,630,720.9	0.02	103.96	3.37	30.89	0.4%
<i>365-Day Inclusion/Exclusion Period</i>													
0-17 Years	0	0	0	0	0	0.0	636,409	483,887.5	0.00	---	---	---	0.0%
18-44 Years	9	9	28	959	1,798	2.9	3,146,221	2,434,758.4	0.00	106.56	3.11	34.25	1.1%
45-64 Years	46	46	112	3,705	7,320	11.6	3,199,137	2,749,632.3	0.01	80.54	2.43	33.08	0.6%
65+ Years	35	35	84	3,046	5,942	9.3	1,989,709	1,805,898.2	0.02	87.03	2.40	36.26	0.3%

Table 2b. Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015 by On- or Off-Label Indication, Inclusion/Exclusion Period, and Age Group

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
All Brintellix Users													
<i>183-Day Inclusion/Exclusion Period</i>													
0-17 Years	280	280	754	23,966	24,638	73.3	11,585,142	12,683,559.2	0.02	85.59	2.69	31.79	100.0%
18-44 Years	9,416	9,478	26,991	829,432	848,344	2,540.8	23,227,285	23,729,085.8	0.41	88.09	2.87	30.73	100.0%
45-64 Years	10,270	10,330	32,210	1,042,094	1,070,023	3,138.6	17,482,068	20,040,947.3	0.59	101.47	3.14	32.35	100.0%
65+ Years	2,056	2,073	6,584	222,417	231,714	662.8	9,156,068	12,185,592.3	0.22	108.18	3.20	33.78	100.0%
<i>365-Day Inclusion/Exclusion Period</i>													
0-17 Years	235	235	633	20,358	20,811	62.1	9,149,385	10,574,776.6	0.03	86.63	2.69	32.16	100.0%
18-44 Years	7,822	7,876	22,714	697,449	713,226	2,134.1	17,600,619	19,245,536.0	0.44	89.17	2.90	30.71	100.0%
45-64 Years	8,959	9,011	28,442	922,523	947,519	2,775.8	14,152,692	17,325,022.3	0.63	102.97	3.17	32.44	100.0%
65+ Years	1,779	1,796	5,760	194,267	202,488	579.1	7,632,573	10,880,076.5	0.23	109.20	3.24	33.73	100.0%
Brintellix Users with an Indication for Brintellix													
<i>183-Day Inclusion/Exclusion Period</i>													
0-17 Years	242	242	670	21,452	21,884	65.4	683,464	449,036.9	0.35	88.64	2.77	32.02	86.4%
18-44 Years	7,951	7,991	22,983	706,097	723,436	2,161.0	3,613,080	2,341,467.0	2.20	88.81	2.89	30.72	84.4%
45-64 Years	8,761	8,807	27,716	896,071	921,885	2,695.4	3,697,521	2,723,068.0	2.37	102.28	3.16	32.33	85.3%
65+ Years	1,800	1,815	5,654	190,605	198,880	569.0	2,530,303	2,051,019.3	0.71	105.89	3.14	33.71	87.5%
<i>365-Day Inclusion/Exclusion Period</i>													
0-17 Years	211	211	585	18,892	19,345	57.4	644,849	508,626.4	0.33	89.54	2.77	32.29	89.8%
18-44 Years	6,838	6,880	20,022	614,558	629,440	1,879.2	3,231,471	2,593,126.9	2.12	89.87	2.93	30.69	87.4%
45-64 Years	7,947	7,990	25,406	824,114	847,884	2,476.9	3,390,383	3,090,722.0	2.34	103.70	3.20	32.44	88.7%
65+ Years	1,644	1,659	5,253	177,393	184,952	529.5	2,367,123	2,419,388.1	0.69	107.90	3.20	33.77	92.4%
Brintellix Users with an Indication for Brintellix and No Indication for Brilinta													
<i>183-Day Inclusion/Exclusion Period</i>													
0-17 Years	242	242	670	21,452	21,884	65.4	675,066	426,421.6	0.36	88.64	2.77	32.02	86.4%
18-44 Years	7,885	7,925	22,767	699,978	717,096	2,142.3	3,524,256	2,191,228.6	2.24	88.77	2.89	30.75	83.7%
45-64 Years	8,413	8,459	26,668	862,884	888,027	2,595.0	3,539,591	2,452,928.1	2.38	102.57	3.17	32.36	81.9%
65+ Years	1,536	1,549	4,860	166,001	173,592	494.5	2,255,871	1,630,312.9	0.68	108.07	3.16	34.16	74.7%
<i>365-Day Inclusion/Exclusion Period</i>													
0-17 Years	211	211	585	18,892	19,345	57.4	636,386	483,787.3	0.33	89.54	2.77	32.29	89.8%
18-44 Years	6,750	6,792	19,746	606,417	621,033	1,854.4	3,145,319	2,430,745.8	2.15	89.84	2.93	30.71	86.3%
45-64 Years	7,460	7,503	23,932	776,565	799,406	2,333.5	3,198,456	2,745,125.8	2.33	104.10	3.21	32.45	83.3%
65+ Years	1,345	1,358	4,391	150,414	157,192	447.3	1,989,837	1,805,276.3	0.68	111.83	3.26	34.26	75.6%



Table 2b. Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015 by On- or Off-Label Indication, Inclusion/Exclusion Period, and Age Group

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
Brintellix Users with an Indication for Brilinta and No Indication for Brintellix													
<i>183-Day Inclusion/Exclusion Period</i>													
0-17 Years	0	0	0	0	0	0.0	11,396	4,659.8	0.00	---	---	---	0.0%
18-44 Years	6	6	31	976	976	2.8	90,017	35,735.3	0.07	162.67	5.17	31.48	0.1%
45-64 Years	37	37	117	3,698	3,818	10.9	611,831	300,116.8	0.06	99.95	3.16	31.61	0.4%
65+ Years	30	30	112	4,413	4,443	13.0	1,590,102	1,009,144.4	0.02	147.10	3.73	39.40	1.5%
<i>365-Day Inclusion/Exclusion Period</i>													
0-17 Years	0	0	0	0	0	0.0	10,736	5,845.4	0.00	---	---	---	0.0%
18-44 Years	5	5	23	736	736	2.1	79,587	43,188.2	0.06	147.20	4.60	32.00	0.1%
45-64 Years	36	36	72	2,712	2,832	8.4	535,367	348,860.1	0.07	75.33	2.00	37.67	0.4%
65+ Years	30	30	83	3,703	3,733	10.9	1,422,491	1,170,647.0	0.02	123.43	2.77	44.61	1.7%

Table 3a. Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Sex

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
All Brilinta Users													
183-Day Inclusion/Exclusion Period													
Female	7,367	7,423	27,258	926,227	1,841,122	2,737.8	30,101,758	35,085,871.9	0.24	125.73	3.70	33.98	100.0%
Male	15,733	15,836	65,341	2,225,422	4,430,058	6,515.7	28,933,863	33,540,442.7	0.54	141.45	4.15	34.06	100.0%
Unknown	2	2	3	90	180	0.3	2,203	2,394.0	0.91	45.00	1.50	30.00	100.0%
365-Day Inclusion/Exclusion Period													
Female	6,383	6,431	23,810	810,771	1,611,500	2,395.5	23,736,300	29,725,880.9	0.27	127.02	3.73	34.05	100.0%
Male	13,551	13,642	56,912	1,940,824	3,863,227	5,678.3	22,733,084	28,288,132.8	0.60	143.22	4.20	34.10	100.0%
Unknown	2	2	3	90	180	0.3	1,646	2,070.8	1.22	45.00	1.50	30.00	100.0%
Brilinta Users with an Indication for Brilinta													
183-Day Inclusion/Exclusion Period													
Female	7,128	7,165	26,485	900,305	1,790,856	2,659.6	1,277,263	877,292.3	5.58	126.31	3.72	33.99	96.8%
Male	15,307	15,380	63,960	2,177,344	4,334,764	6,370.6	1,507,114	1,063,400.0	10.16	142.24	4.18	34.04	97.3%
Unknown	1	1	1	30	60	0.1	169	131.0	5.92	30.00	1.00	30.00	50.0%
365-Day Inclusion/Exclusion Period													
Female	6,241	6,283	23,370	795,585	1,582,202	2,349.8	1,239,085	1,109,086.2	5.04	127.48	3.74	34.04	97.8%
Male	13,295	13,375	56,024	1,909,683	3,801,327	5,585.1	1,440,059	1,322,007.1	9.23	143.64	4.21	34.09	98.1%
Unknown	1	1	1	30	60	0.1	177	181.1	5.65	30.00	1.00	30.00	50.0%
Brilinta Users with an Indication for Brilinta and No Indication for Brintellix													
183-Day Inclusion/Exclusion Period													
Female	4,538	4,551	17,360	593,384	1,182,393	1,747.4	971,427	543,135.5	4.67	130.76	3.83	34.18	61.6%
Male	12,086	12,117	51,871	1,777,887	3,539,911	5,188.1	1,294,523	794,529.2	9.34	147.10	4.29	34.28	76.8%
Unknown	1	1	1	30	60	0.1	146	88.1	6.85	30.00	1.00	30.00	50.0%
365-Day Inclusion/Exclusion Period													
Female	3,631	3,643	14,129	486,581	969,952	1,430.1	844,579	620,836.5	4.30	134.01	3.89	34.44	56.9%
Male	10,022	10,055	43,755	1,499,424	2,986,760	4,371.4	1,166,765	935,080.2	8.59	149.61	4.37	34.27	74.0%
Unknown	1	1	1	30	60	0.1	148	114.4	6.76	30.00	1.00	30.00	50.0%

Table 3a. Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Sex

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
Brilinta Users with an Indication for Brintellix and No Indication for Brilinta													
<i>183-Day Inclusion/Exclusion Period</i>													
Female	62	62	173	5,644	11,076	17.3	6,264,473	4,424,394.7	0.01	91.03	2.79	32.62	0.8%
Male	70	70	175	5,656	10,952	17.5	3,445,745	2,285,742.7	0.02	80.80	2.50	32.32	0.4%
Unknown	0	0	0	0	0	0.0	367	238.8	0.00	---	---	---	0.0%
<i>365-Day Inclusion/Exclusion Period</i>													
Female	39	39	111	3,502	6,824	10.8	5,587,141	4,920,597.5	0.01	89.79	2.85	31.55	0.6%
Male	51	51	113	4,208	8,236	13.0	3,081,967	2,553,293.5	0.02	82.51	2.22	37.24	0.4%
Unknown	0	0	0	0	0	0.0	327	285.4	0.00	---	---	---	0.0%

Table 3b. Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Sex

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
All Brintellix Users													
183-Day Inclusion/Exclusion Period													
Female	14,947	15,041	44,697	1,422,328	1,461,145	4,313.9	30,101,809	35,083,769.2	0.50	95.16	2.99	31.82	100.0%
Male	7,072	7,120	21,842	695,581	713,574	2,101.7	28,938,157	33,553,018.8	0.24	98.36	3.09	31.85	100.0%
Unknown	0	0	0	0	0	0.0	2,203	2,396.5	0.00	---	---	---	N/A
365-Day Inclusion/Exclusion Period													
Female	12,734	12,815	38,386	1,223,177	1,257,365	3,707.9	23,736,512	29,724,250.2	0.54	96.06	3.01	31.87	100.0%
Male	6,059	6,103	19,163	611,420	626,679	1,843.3	22,736,275	28,299,088.0	0.27	100.91	3.16	31.91	100.0%
Unknown	0	0	0	0	0	0.0	1,646	2,073.0	0.00	---	---	---	N/A
Brintellix Users with an Indication for Brintellix													
183-Day Inclusion/Exclusion Period													
Female	12,825	12,893	38,618	1,229,902	1,266,464	3,726.0	6,533,075	4,929,255.0	1.96	95.90	3.01	31.85	85.8%
Male	5,928	5,962	18,405	584,323	599,620	1,764.8	3,676,967	2,635,041.4	1.61	98.57	3.10	31.75	83.8%
Unknown	0	0	0	0	0	0.0	398	295.0	0.00	---	---	---	N/A
365-Day Inclusion/Exclusion Period													
Female	11,343	11,409	34,515	1,101,447	1,134,175	3,334.3	5,922,522	5,586,925.8	1.92	97.10	3.04	31.91	89.1%
Male	5,296	5,331	16,751	533,510	547,445	1,608.8	3,372,834	3,024,573.4	1.57	100.74	3.16	31.85	87.4%
Unknown	0	0	0	0	0	0.0	375	364.1	0.00	---	---	---	N/A
Brintellix Users with an Indication for Brintellix and No Indication for Brilinta													
183-Day Inclusion/Exclusion Period													
Female	12,409	12,476	37,387	1,190,830	1,226,391	3,607.4	6,263,257	4,417,620.9	1.98	95.97	3.01	31.85	83.0%
Male	5,666	5,699	17,578	559,485	574,207	1,689.9	3,445,876	2,283,031.5	1.64	98.74	3.10	31.83	80.1%
Unknown	0	0	0	0	0	0.0	367	238.8	0.00	---	---	---	N/A
365-Day Inclusion/Exclusion Period													
Female	10,807	10,872	33,010	1,052,860	1,084,165	3,186.4	5,586,115	4,914,163.3	1.93	97.42	3.05	31.90	84.9%
Male	4,959	4,992	15,644	499,428	512,810	1,506.3	3,081,812	2,550,486.5	1.61	100.71	3.15	31.92	81.8%
Unknown	0	0	0	0	0	0.0	327	285.4	0.00	---	---	---	N/A

Table 3b. Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Sex

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
Brintellix Users with an Indication for Brilinta and No Indication for Brintellix													
<i>183-Day Inclusion/Exclusion Period</i>													
Female	33	33	106	3,651	3,771	10.8	973,536	546,424.0	0.03	110.64	3.21	34.44	0.2%
Male	40	40	154	5,436	5,466	16.0	1,299,851	803,142.8	0.03	135.90	3.85	35.30	0.6%
Unknown	0	0	0	0	0	0.0	146	89.5	0.00	---	---	---	N/A
<i>365-Day Inclusion/Exclusion Period</i>													
Female	37	37	95	3,531	3,651	10.6	846,054	624,089.8	0.04	95.43	2.57	37.17	0.3%
Male	34	34	83	3,620	3,650	10.7	1,170,767	944,334.9	0.03	106.47	2.44	43.61	0.6%
Unknown	0	0	0	0	0	0.0	148	116.0	0.00	---	---	---	N/A

Table 4a. Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Year

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
All Brilinta Users													
<i>183-Day Inclusion/Exclusion Period</i>													
2013	2,220	2,220	10,385	369,560	734,703	1,087.6	38,417,504	9,047,598.5	0.06	166.47	4.68	35.59	100.0%
2014	10,360	10,373	48,371	1,693,143	3,369,507	4,962.4	45,067,533	34,709,772.9	0.23	163.43	4.67	35.00	100.0%
2015	10,666	10,668	33,846	1,089,036	2,167,149	3,203.8	41,500,076	24,871,337.2	0.26	102.10	3.17	32.18	100.0%
<i>365-Day Inclusion/Exclusion Period</i>													
2013	1,852	1,852	8,822	317,266	630,610	932.2	31,223,586	7,606,795.6	0.06	171.31	4.76	35.96	100.0%
2014	8,717	8,728	41,293	1,446,253	2,878,046	4,236.6	35,081,175	29,185,919.3	0.25	165.91	4.74	35.02	100.0%
2015	9,493	9,495	30,610	988,166	1,966,250	2,905.2	32,938,922	21,223,369.5	0.29	104.09	3.22	32.28	100.0%
Brilinta Users with an Indication for Brilinta													
<i>183-Day Inclusion/Exclusion Period</i>													
2013	2,142	2,142	10,095	360,299	716,183	1,059.7	1,215,215	241,056.2	1.76	168.21	4.71	35.69	96.5%
2014	10,033	10,041	47,257	1,654,881	3,294,392	4,847.3	1,924,888	956,967.1	5.21	164.94	4.71	35.02	96.8%
2015	10,361	10,363	33,094	1,062,499	2,115,104	3,123.3	1,723,129	742,800.1	6.01	102.55	3.19	32.11	97.1%
<i>365-Day Inclusion/Exclusion Period</i>													
2013	1,810	1,810	8,624	310,514	617,106	912.3	1,324,329	292,196.9	1.37	171.55	4.76	36.01	97.7%
2014	8,522	8,533	40,624	1,422,990	2,832,509	4,167.0	1,871,994	1,193,780.6	4.55	166.98	4.77	35.03	97.8%
2015	9,314	9,316	30,147	971,794	1,933,973	2,855.8	1,775,299	945,297.0	5.25	104.34	3.24	32.24	98.1%
Brilinta Users with an Indication for Brilinta and No Indication for Brintellix													
<i>183-Day Inclusion/Exclusion Period</i>													
2013	1,625	1,625	7,955	284,911	567,312	836.0	922,826	170,101.0	1.76	175.33	4.90	35.82	73.2%
2014	7,512	7,515	36,585	1,288,123	2,565,593	3,762.2	1,545,334	668,101.8	4.86	171.48	4.87	35.21	72.5%
2015	7,529	7,529	24,692	798,267	1,589,459	2,337.4	1,343,165	499,549.9	5.61	106.03	3.28	32.33	70.6%
<i>365-Day Inclusion/Exclusion Period</i>													
2013	1,317	1,317	6,550	236,870	471,456	693.9	924,773	192,800.2	1.42	179.86	4.97	36.16	71.1%
2014	6,018	6,021	30,067	1,058,179	2,109,187	3,086.8	1,383,002	776,545.3	4.35	175.84	5.00	35.19	69.0%
2015	6,361	6,361	21,268	690,986	1,376,129	2,020.9	1,249,208	586,685.6	5.09	108.63	3.34	32.49	67.0%

Table 4a. Summary of Brilinta Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Year

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
Brilinta Users with an Indication for Brintellix and No Indication for Brilinta													
<i>183-Day Inclusion/Exclusion Period</i>													
2013	13	13	44	1,102	2,202	3.4	4,324,513	836,267.7	0.00	84.77	3.38	25.05	0.6%
2014	62	62	187	6,203	12,046	18.9	6,800,034	3,403,790.2	0.01	100.05	3.02	33.17	0.6%
2015	57	57	117	3,995	7,780	12.5	6,035,695	2,470,318.2	0.01	70.09	2.05	34.15	0.5%
<i>365-Day Inclusion/Exclusion Period</i>													
2013	4	4	16	540	1,080	1.6	4,300,003	923,929.8	0.00	135.00	4.00	33.75	0.2%
2014	51	51	140	5,030	9,730	15.2	6,094,810	3,763,610.4	0.01	98.63	2.75	35.93	0.6%
2015	35	35	68	2,140	4,250	6.9	5,592,640	2,786,636.3	0.01	61.14	1.94	31.47	0.4%

Table 4b. Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Year

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
All Brintellix Users													
<i>183-Day Inclusion/Exclusion Period</i>													
2013	131	131	402	13,256	15,098	40.2	38,424,566	9,049,679.0	0.00	101.19	3.07	32.98	100.0%
2014	12,500	12,515	41,286	1,343,761	1,382,953	4,059.5	45,072,753	34,715,495.5	0.28	107.50	3.30	32.55	100.0%
2015	9,514	9,515	24,851	760,892	776,667	2,315.8	41,503,340	24,874,010.0	0.23	79.98	2.61	30.62	100.0%
<i>365-Day Inclusion/Exclusion Period</i>													
2013	117	117	360	12,055	13,837	36.5	31,229,457	7,608,555.9	0.00	103.03	3.08	33.49	100.0%
2014	10,570	10,585	35,391	1,153,492	1,186,821	3,481.2	35,085,262	29,190,892.9	0.30	109.13	3.35	32.59	100.0%
2015	8,215	8,216	21,798	669,050	683,385	2,033.4	32,941,436	21,225,962.5	0.25	81.44	2.65	30.69	100.0%
Brintellix Users with an Indication for Brintellix													
<i>183-Day Inclusion/Exclusion Period</i>													
2013	101	101	277	9,152	10,753	28.1	4,656,712	938,640.6	0.02	90.61	2.74	33.04	77.1%
2014	10,587	10,596	35,342	1,149,682	1,185,369	3,469.8	7,143,879	3,773,873.3	1.48	108.59	3.34	32.53	84.7%
2015	8,157	8,158	21,404	655,391	669,962	1,993.0	6,375,616	2,852,077.4	1.28	80.35	2.62	30.62	85.7%
<i>365-Day Inclusion/Exclusion Period</i>													
2013	97	97	264	9,024	10,562	27.7	4,742,047	1,056,992.9	0.02	93.03	2.72	34.18	82.9%
2014	9,307	9,317	31,512	1,027,381	1,058,995	3,097.0	6,525,287	4,263,952.1	1.43	110.39	3.39	32.60	88.1%
2015	7,325	7,326	19,490	598,552	612,063	1,818.5	6,088,565	3,290,918.3	1.20	81.71	2.66	30.71	89.2%
Brintellix Users with an Indication for Brintellix and No Indication for Brilinta													
<i>183-Day Inclusion/Exclusion Period</i>													
2013	97	97	272	9,025	10,626	27.6	4,325,009	836,340.2	0.02	93.04	2.80	33.18	74.0%
2014	10,230	10,239	34,117	1,110,648	1,145,116	3,351.7	6,799,948	3,400,210.9	1.50	108.57	3.33	32.55	81.8%
2015	7,838	7,839	20,576	630,642	644,856	1,917.9	6,030,035	2,464,340.2	1.30	80.46	2.63	30.65	82.4%
<i>365-Day Inclusion/Exclusion Period</i>													
2013	95	95	259	8,874	10,382	27.2	4,300,164	923,950.9	0.02	93.41	2.73	34.26	81.2%
2014	8,846	8,856	29,951	976,274	1,006,431	2,942.8	6,094,439	3,760,239.6	1.45	110.36	3.39	32.60	83.7%
2015	6,912	6,913	18,444	567,140	580,162	1,722.7	5,587,861	2,780,744.7	1.24	82.05	2.67	30.75	84.1%

Table 4b. Summary of Brintellix Use in the Sentinel Distributed Database between September 30, 2013 - September 30, 2015, by On- or Off-Label Indication, Inclusion/Exclusion Period, and Year

	New Users	New Episodes	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users per 1,000 Eligible Members	Days Supplied per User	Dispensings per User	Days Supplied per Dispensing	Percent of Total Users
Brintellix Users with an Indication for Brilinta and No Indication for Brintellix												
<i>183-Day Inclusion/Exclusion Period</i>												
2013	0	0	0	0	0.0	927,199	171,156.5	0.00	---	---	---	0.0%
2014	41	41	169	5,953	17.6	1,551,207	673,425.3	0.03	145.20	4.12	35.22	0.3%
2015	32	32	91	3,134	9.2	1,351,346	505,074.4	0.02	97.94	2.84	34.44	0.3%
<i>365-Day Inclusion/Exclusion Period</i>												
2013	0	0	0	0	0.0	928,753	193,891.8	0.00	---	---	---	0.0%
2014	36	36	90	3,800	11.5	1,387,461	782,088.6	0.03	105.56	2.50	42.22	0.3%
2015	35	35	88	3,351	9.9	1,255,611	592,560.3	0.03	95.74	2.51	38.08	0.4%

Appendix A. List of Generic and Brand Drug Names Used to Define Exposures in this Request

Generic Name	Brand Name
BRILINTA	TICAGRELOR
Brintellix	VORTIOXETINE HYDROBROMIDE

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Depression			
Brintellix	296.2	Major depressive disorder, single episode	ICD-9-CM Diagnosis
Brintellix	296.20	Major depressive disorder, single episode, unspecified	ICD-9-CM Diagnosis
Brintellix	296.21	Major depressive disorder, single episode, mild	ICD-9-CM Diagnosis
Brintellix	296.22	Major depressive disorder, single episode, moderate	ICD-9-CM Diagnosis
Brintellix	296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.25	Major depressive disorder, single episode, in partial or unspecified remission	ICD-9-CM Diagnosis
Brintellix	296.26	Major depressive disorder, single episode in full remission	ICD-9-CM Diagnosis
Brintellix	296.3	Major depressive disorder, recurrent episode	ICD-9-CM Diagnosis
Brintellix	296.30	Major depressive disorder, recurrent episode, unspecified	ICD-9-CM Diagnosis
Brintellix	296.31	Major depressive disorder, recurrent episode, mild	ICD-9-CM Diagnosis
Brintellix	296.32	Major depressive disorder, recurrent episode, moderate	ICD-9-CM Diagnosis
Brintellix	296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	ICD-9-CM Diagnosis
Brintellix	296.36	Major depressive disorder, recurrent episode, in full remission	ICD-9-CM Diagnosis
Brintellix	311	Depressive disorder, not elsewhere classified	ICD-9-CM Diagnosis
Schizophrenia			
Brintellix	295	Schizophrenic disorders	ICD-9-CM Diagnosis
Brintellix	295.0	Simple type schizophrenia	ICD-9-CM Diagnosis
Brintellix	295.00	Simple schizophrenia, unspecified condition	ICD-9-CM Diagnosis
Brintellix	295.01	Simple schizophrenia, subchronic condition	ICD-9-CM Diagnosis
Brintellix	295.02	Simple schizophrenia, chronic condition	ICD-9-CM Diagnosis
Brintellix	295.03	Simple schizophrenia, subchronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.04	Simple schizophrenia, chronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.05	Simple schizophrenia, in remission	ICD-9-CM Diagnosis
Brintellix	295.1	Disorganized type schizophrenia	ICD-9-CM Diagnosis
Brintellix	295.10	Disorganized schizophrenia, unspecified condition	ICD-9-CM Diagnosis
Brintellix	295.11	Disorganized schizophrenia, subchronic condition	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brintellix	295.12	Disorganized schizophrenia, chronic condition	ICD-9-CM Diagnosis
Brintellix	295.13	Disorganized schizophrenia, subchronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.14	Disorganized schizophrenia, chronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.15	Disorganized schizophrenia, in remission	ICD-9-CM Diagnosis
Brintellix	295.2	Catatonic type schizophrenia	ICD-9-CM Diagnosis
Brintellix	295.20	Catatonic schizophrenia, unspecified condition	ICD-9-CM Diagnosis
Brintellix	295.21	Catatonic schizophrenia, subchronic condition	ICD-9-CM Diagnosis
Brintellix	295.22	Catatonic schizophrenia, chronic condition	ICD-9-CM Diagnosis
Brintellix	295.23	Catatonic schizophrenia, subchronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.24	Catatonic schizophrenia, chronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.25	Catatonic schizophrenia, in remission	ICD-9-CM Diagnosis
Brintellix	295.3	Paranoid type schizophrenia	ICD-9-CM Diagnosis
Brintellix	295.30	Paranoid schizophrenia, unspecified condition	ICD-9-CM Diagnosis
Brintellix	295.31	Paranoid schizophrenia, subchronic condition	ICD-9-CM Diagnosis
Brintellix	295.32	Paranoid schizophrenia, chronic condition	ICD-9-CM Diagnosis
Brintellix	295.33	Paranoid schizophrenia, subchronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.34	Paranoid schizophrenia, chronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.35	Paranoid schizophrenia, in remission	ICD-9-CM Diagnosis
Brintellix	295.4	Schizophreniform disorder	ICD-9-CM Diagnosis
Brintellix	295.40	Schizophreniform disorder, unspecified	ICD-9-CM Diagnosis
Brintellix	295.41	Schizophreniform disorder, subchronic	ICD-9-CM Diagnosis
Brintellix	295.42	Schizophreniform disorder, chronic	ICD-9-CM Diagnosis
Brintellix	295.43	Schizophreniform disorder, subchronic with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.44	Schizophreniform disorder, chronic with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.45	Schizophreniform disorder, in remission	ICD-9-CM Diagnosis
Brintellix	295.5	Latent schizophrenia	ICD-9-CM Diagnosis
Brintellix	295.50	Latent schizophrenia, unspecified condition	ICD-9-CM Diagnosis
Brintellix	295.51	Latent schizophrenia, subchronic condition	ICD-9-CM Diagnosis
Brintellix	295.52	Latent schizophrenia, chronic condition	ICD-9-CM Diagnosis
Brintellix	295.53	Latent schizophrenia, subchronic condition with acute exacerbation	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brintellix	295.54	Latent schizophrenia, chronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.55	Latent schizophrenia, in remission	ICD-9-CM Diagnosis
Brintellix	295.6	Schizophrenic disorders, residual type	ICD-9-CM Diagnosis
Brintellix	295.60	Schizophrenic disorders, residual type, unspecified	ICD-9-CM Diagnosis
Brintellix	295.61	Schizophrenic disorders, residual type, subchronic	ICD-9-CM Diagnosis
Brintellix	295.62	Schizophrenic disorders, residual type, chronic	ICD-9-CM Diagnosis
Brintellix	295.63	Schizophrenic disorders, residual type, subchronic with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.64	Schizophrenic disorders, residual type, chronic with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.65	Schizophrenic disorders, residual type, in remission	ICD-9-CM Diagnosis
Brintellix	295.7	Schizoaffective disorder	ICD-9-CM Diagnosis
Brintellix	295.70	Schizoaffective disorder, unspecified	ICD-9-CM Diagnosis
Brintellix	295.71	Schizoaffective disorder, subchronic	ICD-9-CM Diagnosis
Brintellix	295.72	Schizoaffective disorder, chronic	ICD-9-CM Diagnosis
Brintellix	295.73	Schizoaffective disorder, subchronic with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.74	Schizoaffective disorder, chronic with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.75	Schizoaffective disorder, in remission	ICD-9-CM Diagnosis
Brintellix	295.8	Other specified types of schizophrenia	ICD-9-CM Diagnosis
Brintellix	295.80	Other specified types of schizophrenia, unspecified condition	ICD-9-CM Diagnosis
Brintellix	295.81	Other specified types of schizophrenia, subchronic condition	ICD-9-CM Diagnosis
Brintellix	295.82	Other specified types of schizophrenia, chronic condition	ICD-9-CM Diagnosis
Brintellix	295.83	Other specified types of schizophrenia, subchronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.84	Other specified types of schizophrenia, chronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.85	Other specified types of schizophrenia, in remission	ICD-9-CM Diagnosis
Brintellix	295.9	Unspecified schizophrenia	ICD-9-CM Diagnosis
Brintellix	295.90	Unspecified schizophrenia, unspecified condition	ICD-9-CM Diagnosis
Brintellix	295.91	Unspecified schizophrenia, subchronic condition	ICD-9-CM Diagnosis
Brintellix	295.92	Unspecified schizophrenia, chronic condition	ICD-9-CM Diagnosis
Brintellix	295.93	Unspecified schizophrenia, subchronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.94	Unspecified schizophrenia, chronic condition with acute exacerbation	ICD-9-CM Diagnosis
Brintellix	295.95	Unspecified schizophrenia, in remission	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Episodic Mood Disorders			
Brintellix	296	Episodic mood disorders	ICD-9-CM Diagnosis
Brintellix	296.0	Bipolar I disorder, single manic episode	ICD-9-CM Diagnosis
Brintellix	296.00	Bipolar I disorder, single manic episode, unspecified	ICD-9-CM Diagnosis
Brintellix	296.01	Bipolar I disorder, single manic episode, mild	ICD-9-CM Diagnosis
Brintellix	296.02	Bipolar I disorder, single manic episode, moderate	ICD-9-CM Diagnosis
Brintellix	296.03	Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.04	Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.05	Bipolar I disorder, single manic episode, in partial or unspecified remission	ICD-9-CM Diagnosis
Brintellix	296.06	Bipolar I disorder, single manic episode, in full remission	ICD-9-CM Diagnosis
Brintellix	296.1	Manic disorder, recurrent episode	ICD-9-CM Diagnosis
Brintellix	296.10	Manic disorder, recurrent episode, unspecified	ICD-9-CM Diagnosis
Brintellix	296.11	Manic disorder, recurrent episode, mild	ICD-9-CM Diagnosis
Brintellix	296.12	Manic disorder, recurrent episode, moderate	ICD-9-CM Diagnosis
Brintellix	296.13	Manic disorder, recurrent episode, severe, without mention of psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.14	Manic disorder, recurrent episode, severe, specified as with psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.15	Manic disorder, recurrent episode, in partial or unspecified remission	ICD-9-CM Diagnosis
Brintellix	296.16	Manic disorder, recurrent episode, in full remission	ICD-9-CM Diagnosis
Brintellix	296.4	Bipolar I disorder, most recent episode (or current) manic	ICD-9-CM Diagnosis
Brintellix	296.40	Bipolar I disorder, most recent episode (or current) manic, unspecified	ICD-9-CM Diagnosis
Brintellix	296.41	Bipolar I disorder, most recent episode (or current) manic, mild	ICD-9-CM Diagnosis
Brintellix	296.42	Bipolar I disorder, most recent episode (or current) manic, moderate	ICD-9-CM Diagnosis
Brintellix	296.43	Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.44	Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.45	Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission	ICD-9-CM Diagnosis
Brintellix	296.46	Bipolar I disorder, most recent episode (or current) manic, in full remission	ICD-9-CM Diagnosis
Brintellix	296.6	Bipolar I disorder, most recent episode (or current), mixed	ICD-9-CM Diagnosis
Brintellix	296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	ICD-9-CM Diagnosis
Brintellix	296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brintellix	296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	ICD-9-CM Diagnosis
Brintellix	296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	ICD-9-CM Diagnosis
Brintellix	296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	ICD-9-CM Diagnosis
Brintellix	296.7	Bipolar I disorder, most recent episode (or current) unspecified	ICD-9-CM Diagnosis
Brintellix	296.8	Other and unspecified bipolar disorders	ICD-9-CM Diagnosis
Brintellix	296.80	Bipolar disorder, unspecified	ICD-9-CM Diagnosis
Brintellix	296.81	Atypical manic disorder	ICD-9-CM Diagnosis
Brintellix	296.82	Atypical depressive disorder	ICD-9-CM Diagnosis
Brintellix	296.89	Other and unspecified bipolar disorders	ICD-9-CM Diagnosis
Brintellix	296.9	Other and unspecified episodic mood disorder	ICD-9-CM Diagnosis
Brintellix	296.90	Unspecified episodic mood disorder	ICD-9-CM Diagnosis
Brintellix	296.99	Other specified episodic mood disorder	ICD-9-CM Diagnosis
Anxiety Disorders			
Brintellix	300	Anxiety, dissociative and somatoform disorders	ICD-9-CM Diagnosis
Brintellix	300.0	Anxiety states	ICD-9-CM Diagnosis
Brintellix	300.00	Anxiety state, unspecified	ICD-9-CM Diagnosis
Brintellix	300.01	Panic disorder without agoraphobia	ICD-9-CM Diagnosis
Brintellix	300.02	Generalized anxiety disorder	ICD-9-CM Diagnosis
Brintellix	300.09	Other anxiety states	ICD-9-CM Diagnosis
Brintellix	300.1	Dissociative, conversion and factitious disorders	ICD-9-CM Diagnosis
Brintellix	300.10	Hysteria, unspecified	ICD-9-CM Diagnosis
Brintellix	300.11	Conversion disorder	ICD-9-CM Diagnosis
Brintellix	300.12	Dissociative amnesia	ICD-9-CM Diagnosis
Brintellix	300.13	Dissociative fugue	ICD-9-CM Diagnosis
Brintellix	300.14	Dissociative identity disorder	ICD-9-CM Diagnosis
Brintellix	300.15	Dissociative disorder or reaction, unspecified	ICD-9-CM Diagnosis
Brintellix	300.16	Factitious disorder with predominantly psychological signs and symptoms	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brintellix	300.19	Other and unspecified factitious illness	ICD-9-CM Diagnosis
Brintellix	300.2	Phobic disorders	ICD-9-CM Diagnosis
Brintellix	300.20	Phobia, unspecified	ICD-9-CM Diagnosis
Brintellix	300.21	Agoraphobia with panic disorder	ICD-9-CM Diagnosis
Brintellix	300.22	Agoraphobia without mention of panic attacks	ICD-9-CM Diagnosis
Brintellix	300.23	Social phobia	ICD-9-CM Diagnosis
Brintellix	300.29	Other isolated or specific phobias	ICD-9-CM Diagnosis
Brintellix	300.3	Obsessive-compulsive disorders	ICD-9-CM Diagnosis
Brintellix	300.4	Dysthymic disorder	ICD-9-CM Diagnosis
Brintellix	300.5	Neurasthenia	ICD-9-CM Diagnosis
Brintellix	300.6	Depersonalization disorder	ICD-9-CM Diagnosis
Brintellix	300.7	Hypochondriasis	ICD-9-CM Diagnosis
Brintellix	300.8	Somatoform disorders	ICD-9-CM Diagnosis
Brintellix	300.81	Somatization disorder	ICD-9-CM Diagnosis
Brintellix	300.82	Undifferentiated somatoform disorder	ICD-9-CM Diagnosis
Brintellix	300.89	Other somatoform disorders	ICD-9-CM Diagnosis
Brintellix	300.9	Unspecified nonpsychotic mental disorder	ICD-9-CM Diagnosis
Personality Disorders			
Brintellix	301	Personality disorders	ICD-9-CM Diagnosis
Brintellix	301.0	Paranoid personality disorder	ICD-9-CM Diagnosis
Brintellix	301.1	Affective personality disorder	ICD-9-CM Diagnosis
Brintellix	301.10	Affective personality disorder, unspecified	ICD-9-CM Diagnosis
Brintellix	301.11	Chronic hypomanic personality disorder	ICD-9-CM Diagnosis
Brintellix	301.12	Chronic depressive personality disorder	ICD-9-CM Diagnosis
Brintellix	301.13	Cyclothymic disorder	ICD-9-CM Diagnosis
Brintellix	301.2	Schizoid personality disorder	ICD-9-CM Diagnosis
Brintellix	301.20	Schizoid personality disorder, unspecified	ICD-9-CM Diagnosis
Brintellix	301.21	Introverted personality	ICD-9-CM Diagnosis
Brintellix	301.22	Schizotypal personality disorder	ICD-9-CM Diagnosis
Brintellix	301.3	Explosive personality disorder	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brintellix	301.4	Obsessive-compulsive personality disorder	ICD-9-CM Diagnosis
Brintellix	301.5	Histrionic personality disorder	ICD-9-CM Diagnosis
Brintellix	301.50	Histrionic personality disorder, unspecified	ICD-9-CM Diagnosis
Brintellix	301.51	Chronic factitious illness with physical symptoms	ICD-9-CM Diagnosis
Brintellix	301.59	Other histrionic personality disorder	ICD-9-CM Diagnosis
Brintellix	301.6	Dependent personality disorder	ICD-9-CM Diagnosis
Brintellix	301.7	Antisocial personality disorder	ICD-9-CM Diagnosis
Brintellix	301.8	Other personality disorders	ICD-9-CM Diagnosis
Brintellix	301.81	Narcissistic personality disorder	ICD-9-CM Diagnosis
Brintellix	301.82	Avoidant personality disorder	ICD-9-CM Diagnosis
Brintellix	301.83	Borderline personality disorder	ICD-9-CM Diagnosis
Brintellix	301.84	Passive-aggressive personality	ICD-9-CM Diagnosis
Brintellix	301.89	Other personality disorder	ICD-9-CM Diagnosis
Brintellix	301.9	Unspecified personality disorder	ICD-9-CM Diagnosis
Bipolar Depression			
Brintellix	296.5	Bipolar I disorder, most recent episode (or current), depressed	ICD-9-CM Diagnosis
Brintellix	296.50	Bipolar I disorder, most recent episode (or current) depressed, unspecified	ICD-9-CM Diagnosis
Brintellix	296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	ICD-9-CM Diagnosis
Brintellix	296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	ICD-9-CM Diagnosis
Brintellix	296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	ICD-9-CM Diagnosis
Brintellix	296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	ICD-9-CM Diagnosis
Brintellix	296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	ICD-9-CM Diagnosis
Chronic Pain			
Brintellix	338.2	Chronic pain	ICD-9-CM Diagnosis
Brintellix	338.21	Chronic pain due to trauma	ICD-9-CM Diagnosis
Brintellix	338.22	Chronic post-thoracotomy pain	ICD-9-CM Diagnosis
Brintellix	338.28	Other chronic postoperative pain	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brintellix	338.29	Other chronic pain	ICD-9-CM Diagnosis
Post-Traumatic Stress Disorder			
Brintellix	309.81	Posttraumatic stress disorder	ICD-9-CM Diagnosis
Acute Coronary Syndrome			
Brilinta	411.1	Intermediate coronary syndrome	ICD-9-CM Diagnosis
Myocardial Infarction			
Brilinta	410	Acute myocardial infarction	ICD-9-CM Diagnosis
Brilinta	410.0	Acute myocardial infarction of anterolateral wall	ICD-9-CM Diagnosis
Brilinta	410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	ICD-9-CM Diagnosis
Brilinta	410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	410.1	Acute myocardial infarction of other anterior wall	ICD-9-CM Diagnosis
Brilinta	410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.11	Acute myocardial infarction of other anterior wall, initial episode of care	ICD-9-CM Diagnosis
Brilinta	410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	410.2	Acute myocardial infarction of inferolateral wall	ICD-9-CM Diagnosis
Brilinta	410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	ICD-9-CM Diagnosis
Brilinta	410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	410.3	Acute myocardial infarction of inferoposterior wall	ICD-9-CM Diagnosis
Brilinta	410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	ICD-9-CM Diagnosis
Brilinta	410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	410.4	Acute myocardial infarction of other inferior wall	ICD-9-CM Diagnosis
Brilinta	410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.41	Acute myocardial infarction of other inferior wall, initial episode of care	ICD-9-CM Diagnosis
Brilinta	410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	410.5	Acute myocardial infarction of other lateral wall	ICD-9-CM Diagnosis
Brilinta	410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.51	Acute myocardial infarction of other lateral wall, initial episode of care	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brilinta	410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	410.6	Acute myocardial infarction, true posterior wall infarction	ICD-9-CM Diagnosis
Brilinta	410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	ICD-9-CM Diagnosis
Brilinta	410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	410.7	Acute myocardial infarction, subendocardial infarction	ICD-9-CM Diagnosis
Brilinta	410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	ICD-9-CM Diagnosis
Brilinta	410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	410.8	Acute myocardial infarction of other specified sites	ICD-9-CM Diagnosis
Brilinta	410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.81	Acute myocardial infarction of other specified sites, initial episode of care	ICD-9-CM Diagnosis
Brilinta	410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	410.9	Acute myocardial infarction, unspecified site	ICD-9-CM Diagnosis
Brilinta	410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	ICD-9-CM Diagnosis
Brilinta	410.91	Acute myocardial infarction, unspecified site, initial episode of care	ICD-9-CM Diagnosis
Brilinta	410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	ICD-9-CM Diagnosis
Brilinta	412	Old myocardial infarction	ICD-9-CM Diagnosis
Peripheral Arterial Disease			
Brilinta	443.9	Peripheral vascular disease, unspecified	ICD-9-CM Diagnosis
Unstable Angina			
Brilinta	411.1	Intermediate coronary syndrome	ICD-9-CM Diagnosis
Stroke			
Brilinta	430	Subarachnoid hemorrhage	ICD-9-CM Diagnosis
Brilinta	431	Intracerebral hemorrhage	ICD-9-CM Diagnosis
Brilinta	432	Other and unspecified intracranial hemorrhage	ICD-9-CM Diagnosis
Brilinta	432.0	Nontraumatic extradural hemorrhage	ICD-9-CM Diagnosis
Brilinta	432.1	Subdural hemorrhage	ICD-9-CM Diagnosis
Brilinta	432.9	Unspecified intracranial hemorrhage	ICD-9-CM Diagnosis
Brilinta	433.01	Occlusion and stenosis of basilar artery with cerebral infarction	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brilinta	433.11	Occlusion and stenosis of carotid artery with cerebral infarction	ICD-9-CM Diagnosis
Brilinta	433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	ICD-9-CM Diagnosis
Brilinta	433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	ICD-9-CM Diagnosis
Brilinta	433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	ICD-9-CM Diagnosis
Brilinta	433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	ICD-9-CM Diagnosis
Brilinta	434.01	Cerebral thrombosis with cerebral infarction	ICD-9-CM Diagnosis
Brilinta	434.11	Cerebral embolism with cerebral infarction	ICD-9-CM Diagnosis
Brilinta	434.91	Unspecified cerebral artery occlusion with cerebral infarction	ICD-9-CM Diagnosis
Brilinta	436	Acute, but ill-defined, cerebrovascular disease	ICD-9-CM Diagnosis
Brilinta	852.0	Subarachnoid hemorrhage following injury without mention of open intracranial wound	ICD-9-CM Diagnosis
Brilinta	852.00	Subarachnoid hemorrhage following injury, without mention of open intracranial wound, unspecified state of consciousness	ICD-9-CM Diagnosis
Brilinta	852.01	Subarachnoid hemorrhage following injury, without mention of open intracranial wound, no loss of consciousness	ICD-9-CM Diagnosis
Brilinta	852.02	Subarachnoid hemorrhage following injury, without mention of open intracranial wound, brief (less than 1 hour) loss of consciousness	ICD-9-CM Diagnosis
Brilinta	852.03	Subarachnoid hemorrhage following injury, without mention of open intracranial wound, moderate (1-24 hours) loss of consciousness	ICD-9-CM Diagnosis
Brilinta	852.04	Subarachnoid hemorrhage following injury, without mention of open intracranial wound, prolonged (more than 24 hours) loss of consciousness and return to pre-existing conscious level	ICD-9-CM Diagnosis
Brilinta	852.05	Subarachnoid hemorrhage following injury, without mention of open intracranial wound, prolonged (more than 24 hours) loss of consciousness, without return to pre-existing conscious level	ICD-9-CM Diagnosis
Brilinta	852.06	Subarachnoid hemorrhage following injury, without mention of open intracranial wound, loss of consciousness of unspecified duration	ICD-9-CM Diagnosis
Brilinta	852.09	Subarachnoid hemorrhage following injury, without mention of open intracranial wound, unspecified concussion	ICD-9-CM Diagnosis
Brilinta	852.2	Subdural hemorrhage following injury without mention of open intracranial wound	ICD-9-CM Diagnosis
Brilinta	852.20	Subdural hemorrhage following injury, without mention of open intracranial wound, unspecified state of consciousness	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brilinta	852.21	Subdural hemorrhage following injury, without mention of open intracranial wound, no loss of consciousness	ICD-9-CM Diagnosis
Brilinta	852.22	Subdural hemorrhage following injury, without mention of open intracranial wound, brief (less than one hour) loss of consciousness	ICD-9-CM Diagnosis
Brilinta	852.23	Subdural hemorrhage following injury, without mention of open intracranial wound, moderate (1-24 hours) loss of consciousness	ICD-9-CM Diagnosis
Brilinta	852.24	Subdural hemorrhage following injury, without mention of open intracranial wound, prolonged (more than 24 hours) loss of consciousness and return to pre-existing conscious level	ICD-9-CM Diagnosis
Brilinta	852.25	Subdural hemorrhage following injury, without mention of open intracranial wound, prolonged (more than 24 hours) loss of consciousness, without return to pre-existing conscious level	ICD-9-CM Diagnosis
Brilinta	852.26	Subdural hemorrhage following injury, without mention of open intracranial wound, loss of consciousness of unspecified duration	ICD-9-CM Diagnosis
Brilinta	852.29	Subdural hemorrhage following injury, without mention of open intracranial wound, unspecified concussion	ICD-9-CM Diagnosis
Brilinta	852.4	Extradural hemorrhage following injury without mention of open intracranial wound	ICD-9-CM Diagnosis
Brilinta	852.40	Extradural hemorrhage following injury, without mention of open intracranial wound, unspecified state of consciousness	ICD-9-CM Diagnosis
Brilinta	852.41	Extradural hemorrhage following injury, without mention of open intracranial wound, no loss of consciousness	ICD-9-CM Diagnosis
Brilinta	852.42	Extradural hemorrhage following injury, without mention of open intracranial wound, brief (less than 1 hour) loss of consciousness	ICD-9-CM Diagnosis
Brilinta	852.43	Extradural hemorrhage following injury, without mention of open intracranial wound, moderate (1-24 hours) loss of consciousness	ICD-9-CM Diagnosis
Brilinta	852.44	Extradural hemorrhage following injury, without mention of open intracranial wound, prolonged (more than 24 hours) loss of consciousness and return to pre-existing conscious level	ICD-9-CM Diagnosis
Brilinta	852.45	Extradural hemorrhage following injury, without mention of open intracranial wound, prolonged (more than 24 hours) loss of consciousness, without return to pre-existing conscious level	ICD-9-CM Diagnosis
Brilinta	852.46	Extradural hemorrhage following injury, without mention of open intracranial wound, loss of consciousness of unspecified duration	ICD-9-CM Diagnosis

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brilinta	852.49	Extradural hemorrhage following injury, without mention of open intracranial wound, unspecified concussion	ICD-9-CM Diagnosis
Brilinta	853.0	Other and unspecified intracranial hemorrhage following injury, without mention of open intracranial wound	ICD-9-CM Diagnosis
Stent			
Brilinta	00.45	Insertion of one vascular stent	ICD-9-CM Procedure
Brilinta	00.46	Insertion of two vascular stents	ICD-9-CM Procedure
Brilinta	00.47	Insertion of three vascular stents	ICD-9-CM Procedure
Brilinta	00.48	Insertion of four or more vascular stents	ICD-9-CM Procedure
Brilinta	00.55	Insertion of drug-eluting stent(s) of other peripheral vessel(s)	ICD-9-CM Procedure
Brilinta	00.60	Insertion of drug-eluting stent(s) of superficial femoral artery	ICD-9-CM Procedure
Brilinta	00.63	Percutaneous insertion of carotid artery stent(s)	ICD-9-CM Procedure
Brilinta	00.64	Percutaneous insertion of other extracranial artery stent(s)	ICD-9-CM Procedure
Brilinta	00.65	Percutaneous insertion of intracranial vascular stent(s)	ICD-9-CM Procedure
Brilinta	0005T	Transcatheter placement of extracranial cerebrovascular artery stent(s), percutaneous; initial vessel	CPT-3 Procedure
Brilinta	0006T	Transcatheter placement of extracranial cerebrovascular artery stent(s), percutaneous; each additional vessel (List separately in addition to code for primary procedure)	CPT-3 Procedure
Brilinta	0007T	Transcatheter placement of extracranial cerebrovascular artery stent(s), percutaneous, radiological supervision and interpretation, each vessel	CPT-3 Procedure
Brilinta	0075T	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel	CPT-3 Procedure
Brilinta	0076T	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel (List separately in addition to code for primary procedure)	CPT-3 Procedure
Brilinta	36.06	Insertion of non-drug-eluting coronary artery stent(s)	ICD-9-CM Procedure
Brilinta	36.07	Insertion of drug-eluting coronary artery stent(s)	ICD-9-CM Procedure
Brilinta	37205	Transcatheter placement of an intravascular stent(s) (except coronary, carotid, vertebral, iliac, and lower extremity arteries), percutaneous; initial vessel	CPT-4 Procedure

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brilinta	37206	Transcatheter placement of an intravascular stent(s) (except coronary, carotid, vertebral, iliac, and lower extremity arteries), percutaneous; each additional vessel (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	37207	Transcatheter placement of an intravascular stent(s) (except coronary, carotid, vertebral, iliac and lower extremity arteries), open; initial vessel	CPT-4 Procedure
Brilinta	37208	Transcatheter placement of an intravascular stent(s) (except coronary, carotid, vertebral, iliac and lower extremity arteries), open; each additional vessel (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	37215	Transcatheter placement of intravascular stent(s), cervical carotid artery, open or percutaneous, including angioplasty, when performed, and radiological supervision and interpretation; with distal embolic protection	CPT-4 Procedure
Brilinta	37216	Transcatheter placement of intravascular stent(s), cervical carotid artery, open or percutaneous, including angioplasty, when performed, and radiological supervision and interpretation; without distal embolic protection	CPT-4 Procedure
Brilinta	37217	Transcatheter placement of intravascular stent(s), intrathoracic common carotid artery or innominate artery by retrograde treatment, open ipsilateral cervical carotid artery exposure, including angioplasty, when performed, and radiological supervision and interpretation	CPT-4 Procedure
Brilinta	37218	Transcatheter placement of intravascular stent(s), intrathoracic common carotid artery or innominate artery, open or percutaneous antegrade approach, including angioplasty, when performed, and radiological supervision and interpretation	CPT-4 Procedure
Brilinta	37221	Revascularization, endovascular, open or percutaneous, iliac artery, unilateral, initial vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed	CPT-4 Procedure
Brilinta	37223	Revascularization, endovascular, open or percutaneous, iliac artery, each additional ipsilateral iliac vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	37226	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed	CPT-4 Procedure

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brilinta	37227	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed	CPT-4 Procedure
Brilinta	37230	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed	CPT-4 Procedure
Brilinta	37231	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed	CPT-4 Procedure
Brilinta	37234	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	37235	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	37236	Transcatheter placement of an intravascular stent(s) (except lower extremity artery(s) for occlusive disease, cervical carotid, extracranial vertebral or intrathoracic carotid, intracranial, or coronary), open or percutaneous, including radiological supervision and interpretation and including all angioplasty within the same vessel, when performed; initial artery	CPT-4 Procedure
Brilinta	37237	Transcatheter placement of an intravascular stent(s) (except lower extremity artery(s) for occlusive disease, cervical carotid, extracranial vertebral or intrathoracic carotid, intracranial, or coronary), open or percutaneous, including radiological supervision and interpretation and including all angioplasty within the same vessel, when performed; each additional artery (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	37238	Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; initial vein	CPT-4 Procedure
Brilinta	37239	Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; each additional vein (List separately in addition to code for primary procedure)	CPT-4 Procedure

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brilinta	39.90	Insertion of non-drug-eluting peripheral (non-coronary) vessel stents(s)	ICD-9-CM Procedure
Brilinta	4561F	Patient has a coronary artery stent (Peri2)	CPT-2 Procedure
Brilinta	61635	Transcatheter placement of intravascular stent(s), intracranial (eg, atherosclerotic stenosis), including balloon angioplasty, if performed	CPT-4 Procedure
Brilinta	75960	Transcatheter introduction of intravascular stent(s) (except coronary, carotid, vertebral, iliac, and lower extremity artery), percutaneous and/or open, radiological supervision and interpretation, each vessel	CPT-4 Procedure
Brilinta	92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	CPT-4 Procedure
Brilinta	92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	CPT-4 Procedure
Brilinta	92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	CPT-4 Procedure
Brilinta	92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	CPT-4 Procedure
Brilinta	92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	CPT-4 Procedure

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brilinta	92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	92980	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	CPT-4 Procedure
Brilinta	92981	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel (List separately in addition to code for primary procedure)	CPT-4 Procedure
Brilinta	C1027	Stent, coronary, magic wallstent extra short or short coronary self-expanding stent with delivery system, radius 14mm self expanding stent with over the wire delivery system	HCPCS Procedure
Brilinta	C1060	Stent, coronary, acs multi-link tristar coronary stent system and delivery system, acs multi-link ultra coronary stent system note: acs multi-link ultra is effective 01/01/01. acs multi-link tristar was effective 08/01/00.	HCPCS Procedure
Brilinta	C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	HCPCS Procedure
Brilinta	C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	HCPCS Procedure
Brilinta	C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	HCPCS Procedure
Brilinta	C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	HCPCS Procedure
Brilinta	C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	HCPCS Procedure

Appendix B. List of International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) and ICD-9-CM Procedure Codes Used to Define On- and Off-Label Indications in this Request

Exposure	Code	Description	Code Type
Brilinta	C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)	HCPCS Procedure
Brilinta	C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	HCPCS Procedure
Brilinta	C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	HCPCS Procedure
Brilinta	C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (list separately in addition to code for primary procedure)	HCPCS Procedure
Brilinta	G0290	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	HCPCS Procedure
Brilinta	G0291	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel	HCPCS Procedure
Brilinta	S2211	Transcatheter placement of intravascular stent(s), carotid artery, percutaneous, unilateral (if performed bilaterally, use-50 modifier)	HCPCS Procedure

Appendix C. Specifications for Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool, version 2.0, to investigate the frequency of medication errors due to look-a-like and sound-a-like name confusion in the Sentinel Distributed Database (SDD). Brintellix and Brilinta were used as an example. In total, 16 different scenarios were examined in this report.

Enrollment Gap: 45 days
Age Groups: 0-17, 18-44, 45-64, 65+ years
Query Period: September 30, 2013 - September 30, 2015
Coverage Requirement: Drug and Medical
Post-Exposure Enrollment Requirement: 30 days

Scenario	Pre-Exposure Enrollment Requirement	Drug/Exposure								Inclusion/Exclusion Criteria				Event/Outcome	
		Incident Exposure	Incident with respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Inclusion/Exclusion Condition	Care Setting	Include or Exclude	Lookback Start	Lookback End	Event
1	183	Brilinta	Brilinta	183	02	10	10	0	0	None	N/A	N/A	N/A	N/A	None
2	183	Brilinta	Brilinta	183	02	10	10	0	0	ACS, MI, or off-label indication	Any	Include	-183	30	None
3	183	Brilinta	Brilinta	183	02	10	10	0	0	ACS, MI, or off-label indication	Any	Include	-183	30	None
4	183	Brilinta	Brilinta	183	02	10	10	0	0	Depression or off-label indication	Any	Exclude	-183	30	None
5	183	Brilinta	Brilinta	183	02	10	10	0	0	Depression or off-label indication	Any	Include	-183	30	None
6	183	Brilinta	Brilinta	183	02	10	10	0	0	ACS, MI, or off-label indication	Any	Exclude	-183	30	None
7	183	Brilinta	Brilinta	183	02	10	10	0	0	ACS, MI, or off-label indication	Any	Include	-183	30	None
8	183	Brilinta	Brilinta	183	02	10	10	0	0	Depression or off-label indication	Any	Exclude	-183	30	None
10	365	Brilinta	Brilinta	183	02	10	10	0	0	ACS, MI, or off-label indication	Any	Include	-365	30	None

Scenario	Drug/Exposure									Inclusion/Exclusion Criteria				Event/Outcome	
	Pre-Exposure Enrollment Requirement	Incident Exposure	Incident with respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Inclusion/Exclusion Condition	Care Setting	Include or Exclude	Lookback Start	Lookback End	Event
11	365	Brilinta	Brilinta	183	02	10	10	0	0	ACS, MI, or off-label indication	Any	Include	-365	30	None
12	365	Brilinta	Brilinta	183	02	10	10	0	0	Depression or off-label indication	Any	Exclude	-365	30	None
										Depression or off-label indication	Any	Include	-365	30	
13	365	Brintellix	Brintellix	183	02	10	10	0	0	ACS, MI, or off-label indication	Any	Exclude	-365	30	None
14	365	Brintellix	Brintellix	183	02	10	10	0	0	None	N/A	N/A	N/A	N/A	None
15	365	Brintellix	Brintellix	183	02	10	10	0	0	Depression or off-label indication	Any	Include	-365	30	None
										ACS, MI, or off-label indication	Any	Exclude	-365	30	
16	365	Brintellix	Brintellix	183	02	10	10	0	0	ACS, MI, or off-label indication	Any	Include	-365	30	None
										Depression or off-label indication	Any	Exclude	-365	30	